Metformin and Testosterone Interaction: What Women Need to Know

What Is the Interaction Between Metformin and Testosterone?

The combination of metformin and testosterone does not produce a classical pharmacokinetic drug-drug interaction (no shared CYP enzyme or P-glycoprotein pathway is the primary concern). The interaction is predominantly pharmacodynamic: the two drugs push androgen levels and metabolic markers in opposite directions, and each amplifies or blunts the effects of the other in ways that matter clinically for women.

Metformin works by activating AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis, and improving peripheral insulin sensitivity. One key downstream effect is reduced ovarian androgen synthesis, which is why the drug is so widely used in PCOS. Testosterone, whether prescribed as gender-affirming hormone therapy, as treatment for hypoactive sexual desire disorder (HSDD), or as part of a menopause hormone regimen, directly raises circulating androgen levels. The net clinical picture depends on which direction is stronger, and that depends on dose, indication, and the woman's baseline hormonal status.

The Pharmacokinetic Picture

Metformin is excreted renally, almost entirely unchanged, and is a substrate of organic cation transporters OCT1 and OCT2. Testosterone undergoes hepatic metabolism primarily via CYP3A4 and is highly protein-bound to sex-hormone-binding globulin (SHBG). These pathways do not directly compete, so serum levels of one drug do not substantially alter the clearance of the other. A coadministration concern sometimes raised in men, that testosterone raises erythropoiesis and thereby alters renal perfusion enough to slow metformin clearance, has not been studied specifically in women and should be regarded as theoretical.

The Pharmacodynamic Overlap

Four areas of pharmacodynamic overlap matter in clinical practice:

• Insulin sensitivity: Metformin improves it; testosterone at supraphysiologic doses may impair it in some women, though physiologic testosterone replacement in postmenopausal women does not appear to worsen glycemic control significantly.
• Lipid profile: Metformin modestly reduces LDL and triglycerides. Testosterone, particularly oral or high-dose formulations, can reduce HDL and raise LDL, partially countering metformin's benefit.
• Erythropoiesis and hematocrit: Testosterone stimulates red blood cell production. Metformin has no meaningful effect on hematocrit. Polycythemia (hematocrit above 52% in women) becomes a monitoring priority.
• SHBG: Metformin raises SHBG in women with PCOS, which lowers free testosterone. Exogenous testosterone raises total testosterone but may also suppress SHBG over time, complicating interpretation of lab results.

How This Interaction Plays Out Across Life Stages

The clinical meaning of combining these two drugs shifts considerably depending on where a woman is in her reproductive life.

Reproductive Years: PCOS

PCOS affects 8-13% of women of reproductive age worldwide. Women with PCOS have chronically elevated endogenous androgens and insulin resistance, which is why metformin is one of the most commonly prescribed off-label treatments for the condition. In the landmark Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus, metformin was endorsed as a useful adjunct for anovulation and metabolic features in PCOS.

The question of adding exogenous testosterone rarely arises in this group for reproductive purposes. But it does arise in the context of gender-affirming care for transgender and nonbinary individuals who also have PCOS. Here, metformin's androgen-lowering effect runs directly counter to the testosterone therapy goal. Clinicians in this setting typically monitor free testosterone and adjust dose accordingly, rather than discontinuing metformin, because metformin's insulin-sensitizing benefit remains relevant regardless of gender identity.

Perimenopause and Menopause: Metabolic Syndrome Meets HSDD

Postmenopausal women are the demographic most likely to receive both drugs simultaneously. Metabolic syndrome affects roughly 35% of women over 60, and metformin is frequently used for prediabetes or off-label longevity or weight management in this group. Testosterone is increasingly prescribed off-label for HSDD in postmenopausal women; a 2019 systematic review and meta-analysis in The Lancet found that transdermal testosterone significantly improved sexual function scores versus placebo in postmenopausal women.

In this population, the pharmacodynamic interaction most worth watching is the lipid axis. Postmenopausal women already have a less favorable lipid profile than premenopausal women. Testosterone, especially if prescribed at doses above those studied in randomized trials, can further reduce HDL. Metformin provides partial counterbalance, but the net result should be confirmed with a fasting lipid panel at 3 months after any dose change.

Trying to Conceive

Women with PCOS who are trying to conceive may be on metformin as part of an ovulation-induction protocol. ACOG Practice Bulletin 194 (Polycystic Ovary Syndrome) notes that metformin may improve ovulation rates and reduce first-trimester miscarriage in PCOS. Exogenous testosterone has no role in this setting and is absolutely contraindicated (see pregnancy section below). There is no scenario in which a woman trying to conceive should be prescribed exogenous testosterone alongside metformin.

Mechanism Deep Dive: Why Metformin Lowers Androgens in Women

This is worth understanding in detail because it changes how you interpret testosterone lab values if you are on metformin.

Metformin reduces androgen production through at least three pathways:

1. AMPK activation in theca cells: By activating AMPK in ovarian theca cells, metformin reduces the expression of steroidogenic enzymes, including CYP17A1, which catalyzes the conversion of progesterone and pregnenolone to androgens. This mechanism was described in a 2001 study in the Journal of Clinical Endocrinology and Metabolism showing that metformin suppressed ovarian P450c17alpha activity in women with PCOS.
2. Insulin lowering: By reducing hyperinsulinemia, metformin removes a key driver of ovarian androgen overproduction. High insulin acts synergistically with LH to stimulate theca cell androgen synthesis.
3. SHBG elevation: Metformin raises hepatic SHBG production (partly because it reduces insulin, which suppresses SHBG), increasing the protein that binds free testosterone and thereby reducing biologically active androgen.

This means that if you are on metformin and your clinician orders a total testosterone level, the result will be lower than it would be off metformin. If exogenous testosterone is then prescribed (say, for HSDD), the dose calibration needs to account for metformin's androgen-suppressing background effect. A woman on 1,500 mg metformin daily may need a slightly different testosterone titration endpoint than a woman not on metformin, because her baseline free testosterone starts lower.

Polycythemia: The Risk That Gets Missed in Women

Polycythemia secondary to testosterone therapy is a well-documented concern in men, but it receives far less attention in women. The Endocrine Society's 2019 guideline on testosterone therapy in women notes that hematocrit should be monitored, though the absolute risk of polycythemia at female-range doses is substantially lower than in men.

At doses used for HSDD (approximately 150-300 mcg/day transdermally, which is roughly one-tenth of a male dose), clinically significant polycythemia is rare. At higher doses used in gender-affirming care, the risk is more meaningful. Metformin does not protect against polycythemia. It does not raise hematocrit, but it also does not lower it.

Monitoring recommendation: Check CBC (specifically hematocrit and hemoglobin) at baseline, at 3 months after starting or dose-escalating testosterone, and then every 6 months while on combined therapy. If hematocrit exceeds 52% in a woman, testosterone dose reduction or temporary discontinuation should be considered before attributing the finding to another cause.

Lipid Monitoring on Combined Therapy

Metformin produces modest but real lipid benefits. In the UKPDS 34 trial, metformin reduced total cholesterol by approximately 0.1 mmol/L and LDL by approximately 0.12 mmol/L in overweight patients with type 2 diabetes.

Testosterone's lipid effects in women depend heavily on the route of administration:

• Transdermal testosterone at physiologic doses has minimal adverse lipid effects and may slightly reduce triglycerides in insulin-resistant women.
• Oral testosterone undecanoate bypasses first-pass metabolism incompletely and has a more variable lipid impact.
• Injectable testosterone at doses used in gender-affirming care can reduce HDL by 10-20% and raise LDL.

The net lipid effect on combined therapy is not predictable from either drug alone. A fasting lipid panel should be checked before starting testosterone if a woman is already on metformin, and then at 3 months and 12 months.

Glucose and HbA1c: Does Testosterone Blunt Metformin's Effect?

The evidence here is mixed and population-specific.

In women with PCOS, testosterone is both a symptom and a driver of insulin resistance. Reducing endogenous testosterone (via metformin or anti-androgens) tends to improve insulin sensitivity. Adding exogenous testosterone back creates a counterforce, though the magnitude depends on dose.

In postmenopausal women, a 2014 randomized trial in the Journal of Clinical Endocrinology and Metabolism found that transdermal testosterone at doses targeting a mid-normal premenopausal range did not significantly worsen insulin sensitivity or HbA1c. So for women using testosterone for HSDD at standard doses, significant glycemic deterioration is not expected. HbA1c should still be re-checked at 6 months after initiating testosterone in any woman on metformin for glucose management.

Pregnancy and Lactation Safety: A Required Assessment

Metformin in Pregnancy

Metformin is FDA Pregnancy Category B: animal reproduction studies have not shown fetal risk, and no adequate well-controlled studies in pregnant women have shown a risk in the first trimester. Metformin crosses the placenta freely and reaches fetal circulation at concentrations similar to maternal levels.

ACOG recommends metformin as an acceptable option for glycemic management in gestational diabetes mellitus (GDM) when insulin is not available or acceptable, though some providers continue to prefer insulin as first-line given longer-term follow-up data gaps for offspring. Metformin is also continued through the first trimester in many PCOS patients to reduce miscarriage risk, though the evidence for this practice is debated.

In lactation, metformin is excreted in breast milk at low concentrations. A 2005 pharmacokinetic study found infant metformin exposure through breast milk was approximately 0.28% of the weight-adjusted maternal dose, which is considered low risk. Most guidelines, including those from the Academy of Breastfeeding Medicine, consider metformin compatible with breastfeeding.

Testosterone in Pregnancy

Testosterone is absolutely contraindicated in pregnancy. It is FDA Pregnancy Category X: testosterone causes virilization of female fetuses. The drug crosses the placenta. No safe dose in pregnancy exists.

Any woman of reproductive potential who is prescribed exogenous testosterone must use reliable contraception. This is not optional. If you are using testosterone for HSDD or gender-affirming purposes and there is any possibility of pregnancy, contraception is mandatory.

Testosterone is also contraindicated in breastfeeding. Androgens suppress lactation and may transfer to the infant through breast milk.

Practical point: If you are on metformin for PCOS and your clinician discusses adding testosterone for any reason, a pregnancy test and contraception review should happen before the first testosterone dose is dispensed.

Who This Combination Is Right For (and Who Should Pause)

Likely appropriate with monitoring

• Postmenopausal women using metformin for prediabetes or metabolic syndrome who are prescribed low-dose transdermal testosterone for confirmed HSDD, with normal baseline CBC and lipids.
• Transgender men or nonbinary individuals with PCOS on metformin who are beginning gender-affirming testosterone therapy, with a plan for more frequent lab monitoring of testosterone levels, hematocrit, and HbA1c.
• Women in perimenopause with insulin resistance and emerging sexual health concerns who are under close metabolic follow-up.

Requires extra caution or reassessment

• Women with baseline polycythemia or hemoglobin above the upper limit of normal before starting testosterone.
• Women with poorly controlled diabetes (HbA1c above 9%): adding testosterone at anything above physiologic replacement doses may further worsen glycemic control and should be deferred until glucose is stabilized.
• Women with significant dyslipidemia, particularly low HDL or elevated triglycerides, where testosterone could worsen the lipid profile beyond what metformin offsets.
• Women with a history of thromboembolic events, since polycythemia raises viscosity and thrombotic risk.

Not appropriate

• Women who are pregnant or trying to conceive: testosterone is absolutely contraindicated regardless of metformin use.
• Women actively breastfeeding: testosterone is contraindicated; metformin alone is compatible with lactation.

Monitoring Protocol: Practical Lab Schedule

The table below summarizes what to check and when for a woman on both metformin and exogenous testosterone.

| Lab | Baseline | 3 months | 6 months | 12 months | Annually thereafter | |---|---|---|---|---|---| | HbA1c | Yes | Yes | Yes | Yes | Yes | | Fasting glucose | Yes | Yes | Yes | Yes | Yes | | Fasting lipid panel | Yes | Yes | No | Yes | Yes | | CBC (hematocrit, Hgb) | Yes | Yes | Yes | Yes | Yes | | Total and free testosterone | Yes | Yes | Yes | Yes | Yes | | SHBG | Yes | No | Yes | Yes | Yes | | Renal function (eGFR) | Yes | No | Yes | Yes | Yes |

Metformin requires adequate renal function for safe use. The FDA label contraindicates metformin when eGFR falls below 30 mL/min/1.73 m² and advises caution between 30-45 mL/min/1.73 m².

Evidence Gap Disclosure

Direct randomized controlled trial data on the co-administration of metformin and testosterone specifically in women is essentially absent. The clinical guidance above is synthesized from:

• PCOS trials studying metformin's effect on endogenous androgen levels.
• Postmenopausal testosterone trials (largely using transdermal formulations at low doses).
• Male hypogonadism data on testosterone's metabolic effects (extrapolated with significant caution, given known sex differences in androgen physiology).
• Pharmacokinetic studies of each drug individually.

The Endocrine Society has explicitly noted that evidence for testosterone therapy in women remains thinner than for men, and that long-term safety data beyond 24 months are lacking. Women with PCOS, postmenopausal women, and transgender individuals are meaningfully different populations, and trial data should not be freely extrapolated across them.

Dosing Considerations When Both Drugs Are Prescribed

Standard metformin dosing for type 2 diabetes runs from 500 mg twice daily up to 2,550 mg daily as the FDA-approved maximum. For PCOS (off-label), doses of 1,000-2,000 mg daily are most common in practice.

Testosterone dosing in women is highly formulation-dependent:

• Transdermal testosterone (compounded or off-label use of male products at fraction of dose): typically 150-300 mcg/day for HSDD.
• Injectable testosterone enanthate or cypionate in gender-affirming care: typically 50-100 mg every 1-2 weeks, titrated to target total testosterone in the mid-to-high male range.

Because metformin lowers SHBG and reduces endogenous androgen production, women on higher metformin doses may show a lower baseline free testosterone before any exogenous testosterone is prescribed. Clinicians should document baseline free testosterone while on metformin rather than assuming a drug-naive reference range applies.

The Global Consensus Position Statement on testosterone therapy for women (2019), endorsed by ISSWSH, NAMS, BMS, and other societies, recommends targeting a serum testosterone concentration in the physiologic premenopausal female range and not exceeding it. This target becomes harder to interpret when metformin is simultaneously suppressing endogenous production, which is a reason to measure free testosterone specifically rather than total testosterone alone.

Practical Counseling Points for Your Appointment

When you speak with your clinician about taking metformin and testosterone together, these are the specific questions worth raising:

1. What is my baseline free testosterone (not just total) while on my current metformin dose?
2. What formulation and dose of testosterone are you prescribing, and what serum level are you targeting?
3. How will we distinguish metformin's androgen-suppressing effect from an under-dose of testosterone in follow-up labs?
4. What is my plan for contraception if I am premenopausal and being prescribed testosterone?
5. Should my lipid panel and CBC be rechecked at 3 months specifically, given the overlap in metabolic effects?

A straightforward lab plan agreed upon before starting combined therapy avoids ambiguous results six months later.